Inhaled mometasone furoate: A review of its use in adults and adolescents with persistent asthma

Drugs

Volumn 61, Issue 9, 2001, Pages 1325-1350

  Sharpe, M ^a   Jarvis, B ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CYTOCHROME P450 3A4; DEXAMETHASONE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PREDNISONE; TRIAMCINOLONE ACETONIDE;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; IN VIVO STUDY; REVIEW; THRUSH; TITRIMETRY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0034886238     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161090-00011     Document Type: Review

References (84)

1. Global strategy for asthma management and prevention
2. Efficacy of inhaled corticosteroids in asthma
3. Inflammatory events in asthma: An expanding equation
4. Asthma: From bronchoconstriction to airways inflammation and remodeling
5. Mechanisms of action of glucocorticoids in asthma
6. Inhaled and nasal corticosteroids: Factors affecting the risks of systemic adverse effects
7. Topical mometasone: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders
8. Mometasone furoate: A review of its intranasal use in allergic rhinitis
9. Efficacy and safety of inhaled corticosteroids
10. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids
11. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines
12. + T cells
13. An in vitro comparison of commonly used topical glucocorticoid preparations
14. Glucocorticosteroids inhibit leukotriene production
15. Corticosteroids inhibit rhinovirus-induced intercellular adhesion molecule-1 up-regulation and promoter activation on respiratory epithelial cells
16. Cytokine inhibition by a novel steroid, mometasone furoate
17. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice
18. Effect of low doses of mometasone furoate (MF) dry powder inhaler (DPI) on allergen-induced asthmatic responses
19. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma
20. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids
21. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses
22. Dose-ranging study of a new steroid for asthma: Mometasone furoate dry powder inhaler
23. Long-term safety of mometasone furoate (MF) administered by dry powder inhaler (DPI) in patients with moderate persistent asthma
24. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler
25. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler
26. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis
27. Bioavailability and metabolism of mometasone fuorate following administration by metered-dose and dry-powder inhalers in healthy human volunteers
28. The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild to moderate persistent asthma
29. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered-dose inhaler
30. The pharmacokinetics of mometasone furoate administered by dry powder inhaler in patients with chronic liver disease
31. Once-daily, evening dosing with mometasone furoate (MF) improves pulmonary function in patients with mild to moderate asthma
32. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma
33. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma
34. Mometasone furoate: Efficacy and safety in moderate asthma compared with beclomethasone dipropionate
35. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator
36. Mometasone furoate 400 mcg once daily is more effective than budesonide 400 mcg once daily in improving pulmonary function in patients with moderate persistent asthma
37. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma
38. The safety and efficacy of mometasone furoate administered by dry powder inhaler in patients previously maintained on high doses of prescribed inhaled corticosteroids
39. Mometasone furoate therapy improves asthma symptoms in addition to pulmonary function in patients previously maintained on high doses of inhaled corticosteroids (ICS)
40. Clinical assessment of inspiratory airflow profiles with the new mometasone furoate dry powder inhaler (MF-DPI)
41. Retention of dose uniformity with the new mometasone furoate dry powder inhaler (MF-DPI)
42. Dose delivery and dose uniformity of the mometasone furoate dry powder inhaler at different flow rates
43. An easy-to-use dry-powder inhaler
44. Long term use of once-daily mometasone furoate is effective and well tolerated in patients with mild to moderate persistent asthma
45. Rapid onset of action of mometasone furoate (MF) administered once daily by dry powder inhaler (DPI)
46. Mometasone furoate administered by metered dose inhaler reduces oral prednisone requirements and improves pulmonary function of patients with severe persistent asthma
47. The British guidelines on asthma management 1995 review and position statement
48. The use of inhaled corticosteroids in asthma
49. Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages ≤500 μg/day in adults and adolescents with mild to moderate asthma
50. Budesonide inhalation suspension: A review of its use in infants, children and adults with inflammatory respiratory disorders
51. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma
52. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics
53. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomized, double-blind, parallel-group controlled trial
54. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma
55. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial
56. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma
57. Comparison of fluticasone propionate and sodium cromoglycate for the treatment of childhood asthma (an open parallel group study)
58. Modern drug treatment of chronic asthma
59. Safety of inhaled and intranasal corticosteroids: Lessons for the new millennium
60. Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers
61. Asthma pharmacotherapy and utilization by children in 3 managed care organizations
62. Comparison with national asthma management guidelines and specialty care: A health maintenance organization experience
63. Preventive pharmacologic therapy among asthmatics: Five years after publication of guidelines
64. Guidelines and realities of asthma management: The Philadelphia story
65. Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994
66. Bronchial asthma: Still an inadequately assessed and improperly treated disease
67. Undertreatment in a non-selected population of adult patients with asthma
68. Prevalence of asthma symptoms, diagnosis, and treatment in 12-14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK)
69. 2-agonists for the treatment of asthma in Quebec: A population-based utilization review
70. Low-dose inhaled corticosteroids and the prevention of death from asthma
71. Actual use of inhaled corticosteroids and risk of hospitalisation: A case-control study
72. Inhaled steroids and the risk of hospitalization for asthma
73. Prescribing and hospital admissions for asthma in east London
74. Are asthma medications and management related to deaths from asthma?
75. Insight into patient dissatisfaction with asthma treatment
76. Once-daily inhaled corticosteroids in mild to moderate asthma: Improving acceptance of treatment
77. Rationale for once-daily therapy in asthma: Compliance issues
78. Chronobiology of asthma
79. Timing of prednisone and alterations of airways inflammation in nocturnal asthma
80. Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy